ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
A bibliometric and critical trend analysis of the anti-cancer potential of Withania somnifera during 2000-2024.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains among the most common causes of mortality and morbidity globally. For millennia, people have utilized herbal medicine for the treatment of various illnesses, including cancer. Multiple research investigations have demonstrated that Withania somnifera possesses significant anti-cancer potential by targeting multiple cancer signalling pathways. Currently, many articles are published regarding Withania somnifera as an anti-cancer agent; however, no SCOPUS-based bibliometric study encompassing a critical analysis of research trends on the subject has been conducted thus far. This review study provides a concise overview of 272 articles published between 2000 and 2024, focusing on research trends and bibliometric studies of anti-cancer properties of Withania somnifera. The article is structured into two main sections. The first section explores global trends, performance analysis metrics, and citation-related metrics. The final section presents a bibliometric evaluation of the research. Data were retrieved from SCOPUS using specific keywords and then manually curated to eliminate duplicates. VOS viewer (version 1.6.20) and Microsoft Excel 2019 were utilized for data visualization. The output of publications about this subject domain reached its peak in 2024. Academia and industry collaborated to publish 2.20% of the articles. The USA (125), India (112), the Department of Pharmacology and Chemical Biology at the University of Pittsburgh (25), the Journal of Ethnopharmacology (25), Withania somnifera (124), and Renu Wadhwa (24) were the most prolific entities in terms of country, institution, publisher, keyword, and author. Withaferin A (47) was the most utilized bioactive compound against cancer, particularly breast cancer (15 studies). Despite the advantageous anti-cancer attributes of Withania somnifera, there remains a deficiency in areas such as clinical data, pharmacokinetic characteristics, safety and toxicity assessments, and effective formulations, which impedes the progression of this potent natural product into clinical development.
Indexed as
Identifiers
41148252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.